IMPROVE study: initiation of biphasic insulin BIAsp30 in type 2 diabetics

被引：0

作者：

Valensi, Paul ^{[1
]}

机构：

[1] Hop Jean Verdier, AH HP, Serv Endocrinol Diabetol Nutr, Bondy, France

来源：

METABOLISMES HORMONES DIABETES ET NUTRITION | 2008年 / 12卷 / 06期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：222 / 223

页数：2

共 50 条

[1] The IMPROVE study, an observational study of initiation of insulin biphasic BIAsp30 in clinical practice. Circumstances of initiation, tolerance and efficacy
Valnsi, P.
[J]. DIABETES & METABOLISM, 2009, 35 : A57 - A57
[2] Comparison of biphasic insulin aspart (BIAsp30) and insulin glargine (IGlarg) during isoglycaemic clamp studies in persons with type 2 diabetes
Luzio, SD
Peter, R
Dunseath, GJ
Pauvaday, V
Owens, DR
[J]. DIABETES, 2004, 53 : A136 - A136
[3] Biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) allow patients with type 2 diabetes to reach A1C target: The PRIEFER study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
[J]. DIABETES, 2006, 55 : A123 - A123
[4] Patients with Type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin-30 (BHI30): data from the REACH study
McNally, PG
Nelson, G
Fitch, M
[J]. DIABETOLOGIA, 2004, 47 : A327 - A327
[5] A COMPARISON OF BIPHASIC INSULIN ASPART (BIASP30) WITH BIPHASIC HUMAN INSULIN (BHI30) FOR TYPE 2 DIABETES MELLITUS IN REAL CLINICAL PRACTICE - A SYSTEMATIC REVIEW AND META-ANALYSIS
Wojciechowski, P.
Gaweska, M.
Caban, A.
Jurkiewicz, B.
Plisko, R.
Rys, P.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A157 - A157
[6] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (IDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
Liebl, Andreas
Prager, Rudolf
Kaiser, Marcel
Binz, Katharina
Gallwitz, Baptist
[J]. DIABETES, 2006, 55 : A460 - A461
[7] Dosing recommendations for biphasic insulin aspart 30 (BIAsp30), insulin detemir (lDet) and insulin aspart (IAsp) from the PREFER treat-to-target study
Liebl, A.
Compion, G.
Prager, R.
Binz, K.
Kaiser, M.
Gallwitz, B.
[J]. DIABETIC MEDICINE, 2007, 24 : 75 - 75
[8] Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes
Valensi, Paul
[J]. DIABETES METABOLIC SYNDROME AND OBESITY, 2009, 2 : 61 - 71
[9] Improved Safety and Efficacy Profile in Patients with Type 2 Diabetes Treated with Biphasic Insulin Aspart 30 (BIAsp 30): Iran Subgroup of the IMPROVE Study
Esteghamati, Alireza
Rajabian, Reza
Amini, Masoud
Bahrami, Amir
Khamseh, Mohammad Ebrahim
Ardekani, Mohammad Afkhami
Rizi, Ehsan Parvaresh
[J]. DIABETES, 2009, 58 : A527 - A527
[10] Effect of biphasic insulin aspart 30/70 (BIAsp30) in combination with metformin on glycaemic control in subjects with type 2 diabetes not optimally controlled on oral antidiabetic agents
Naiker, P.
Makan, H. A.
Omar, M. A. K.
Kedijang, T.
Kong, L. L. L.
[J]. DIABETOLOGIA, 2006, 49 : 599 - 600

← 1 2 3 4 5 →